Engineerm Life Sciences, Stock Price -4.92% at This Time... Institutional Investors Net Buy 11,127 Shares in Last 5 Days

As of 12:30 PM on the 7th, Enzychem Lifesciences is trading at 117,800 KRW, down 4.92% from the previous day. The trading volume is 143,200 shares, which is about 42.28% of the previous day's volume. Enzychem Lifesciences is known as a global new drug development and active pharmaceutical ingredient (API) company.

On October 6, analyst Kim Taeyeop of Hanyang Securities stated, "The company obtained Phase 2 approval from the US FDA for its EC-18 COVID-19 pipeline on August 7 and recently signed a contract with PRA, a major CRO in the US. Upon successful completion of Phase 2 clinical trials and obtaining EUA, revenue generation is expected through technology transfer and API sales. The advantage of in-house production facilities is an important factor that adds further expectations to the profitability of the company's pipeline." He set the target price for Enzychem Lifesciences at 229,000 KRW.

Over the past five days, individual investors have net sold 6,883 shares of Enzychem Lifesciences, while foreign investors and institutions have net sold 1,173 shares and net bought 11,127 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.